Polyphenol-rich juices reduce blood pressure measures in a randomised controlled trial in high normal and hypertensive volunteers

Torunn Elisabeth Tjelle1, Linda Holtung1,2, Siv Kjølsrud Bøhn1, Kjersti Aaby2, Magne Thoresen3, Siv Ashild Wiik1, Ingvild Paur1, Anette Solli Karlsen1, Kjetil Retterstøl1, Per Ole Iversen1,4 and Rune Blomhoff1,5*

1Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, PO Box 1046, Blindern, 0317 Oslo, Norway
2NOFIMA, Norwegian Institute of Food, Fisheries and Aquaculture Research, Osloveien 1, NO-1130 Ås, Norway
3Department of Biostatistics, University of Oslo, Oslo, Norway
4Department of Hematology, Oslo University Hospital, Oslo, Norway
5Division of Cancer, Transplantation and Surgery, Oslo University Hospital, Oslo, Norway

(Submitted 7 August 2014 – Final revision received 1 February 2015 – Accepted 3 February 2015 – First published online 31 July 2015)

Abstract
Intake of fruits and berries may lower blood pressure (BP), most probably due to the high content of polyphenols. In the present study, we tested whether consumption of two polyphenol-rich juices could lower BP. In a randomised, double-blinded, placebo-controlled trial of 12 weeks, 134 healthy individuals, aged 50–70 years, with high normal range BP (130/85–139/89 mmHg, seventy-two subjects) or stage 1-2 hypertension (140/90–179/109 mmHg, sixty-two subjects), were included. They consumed 500 ml/d of one of either (1) a commercially available polyphenol-rich juice based on red grapes, cherries, chokeberries and bilberries; (2) a juice similar to (1) but enriched with polyphenol-rich extracts from blackcurrant press-residue or (3) a placebo juice (polyphenol contents 245·5, 305·2 and 76 mg/100 g, respectively). Resting BP was measured three times, with a 1 min interval, at baseline and after 6 and 12 weeks of intervention. Systolic BP significantly reduced over time (6 and 12 weeks, respectively) in the pooled juice group compared with the placebo group in the first of the three measurements, both for the whole study group (6·9 and 3·4 mmHg; \(P = 0·01\)) and even more pronounced in the hypertensive subjects when analysed separately (7·3 and 6·8 mmHg; \(P = 0·04\)). The variation in the BP measurements was significantly reduced in the pooled juice group compared with the placebo group (1·4 and 1·7 mmHg; \(P = 0·03\)). In conclusion, the present findings suggest that polyphenol-rich berry juice may contribute to a BP- and BP variability lowering effect, being more pronounced in hypertensive than in normotensive subjects.

Key words: Polyphenols: Blood pressure: Berries: Juices: Intervention study: Blood pressure variability: Clinical trials

Intake of fruit and vegetables have been associated with a reduced risk of CVD\(^ (1,2)\). Fruits and vegetables contain various polyphenols that have been suggested to contribute to this protective effect\(^ (3,4)\).

Polyphenols constitute a large family of natural compounds widely found in plant foods. The main function of polyphenols in plants is to provide protection from various types of stress and cellular damages. Each polyphenol molecule comprises two or more phenol units. The number and structure of these phenol units make each polyphenol compound unique with regard to their bioavailability. Moreover, due to their individual bioactivities, absorption\(^ (5,6)\), metabolism and cellular accumulation, as well as specific interaction with various signalling molecules, enzymes, and transcription factors, may vary\(^ (7)\). Therefore, it is likely that polyphenols from different fruits and berries will vary in their potential to exert effects on outcome measures in intervention studies. It has been shown that polyphenols have favourable effects on platelet aggregation\(^ (8–10)\), blood pressure (BP)\(^ (8,9,11)\) and blood lipid composition\(^ (12,15)\), factors that are associated with CVD. Some studies have identified specific polyphenols with the ability to reduce BP, such as quercetin\(^ (14)\). However, whole foods seem to be more effective than supplements in the prevention of CVD\(^ (15)\), possibly because whole foods provide a

Abbreviations: ALAT, alanine transaminase; BP, blood pressure; BP1, first blood pressure measurement; BP mean, mean of blood pressure measurement number two and three; BPV, blood pressure variability; DBP, diastolic blood pressure; DBP1, first diastolic blood pressure; DBP mean, mean diastolic blood pressure; SBP, systolic blood pressure; SBP1, first systolic blood pressure; SBP mean, mean systolic blood pressure; SD, standard deviation.

* Corresponding author: R. Blomhoff, fax +47 22851396, email rune.blomhoff@medisin.uio.no
greater variety of polyphenols. In addition, reportedly combination of several different polyphenols may exert synergistic effects. How polyphenols can relax vascular tone is not known; however, modulation of the balance between NO and endothelin, e.g. via improved antioxidative status, might be involved.

It has been well established that hypertension is a strong predictor for cardiovascular morbidity and mortality, but also fluctuations and variability in BP correlated with disease progression. Rothwell et al. showed that both visit-to-visit variability and maximum systolic blood pressure (SBP) are strong predictors for strokes, independent of mean SBP. In the review by Parati et al., it is reported that variability of short-term BP (within 24 h) has been closely associated with the development, progression and severity of cardiac, vascular and renal organ damages independently of mean BP.

Healthy foods taken in a liquid form can be easily added to a habitual diet. However, the effects of polyphenol-rich juices on BP have not been evaluated. Hence, we hypothesised that intake of such juices would lower BP and/or lead to a more favourable profile of risk factors for CVD in apparently healthy subjects. In the present 12-week, randomised, placebo-controlled intervention study, we tested the effect of a polyphenol-rich juice (MANA Blue) based on red grapes, cherries, chokeberries and bilberries, and a juice (Optijuice) in which MANA Blue has an added polyphenol-rich extract from blackcurrant press-residue. Following a strict procedure, three measurements of SBP and diastolic blood pressure (DBP) were recorded at each visit, and changes in (1) the first blood pressure of three measurements (BP1); (2) the mean of blood pressure measurement number two and three of SBP and DBP; and (3) blood pressure variability (BPV), another predictor of cardiovascular incidents, were analysed. In addition, lipids and other blood parameters associated with CVD were determined.

Subjects and methods

Study beverages

Three different beverages were used in the present study: placebo; MANA Blue; Optijuice. Table 1 shows the nutrient and chemical characteristics of the beverages, whereas the online supplementary Table S1 shows the details and changes in content over time. MANA Blue (MANA Blue, grape, bilberry and chokeberry juice; TINE SA) is a commercially available product containing red grape (Vitis vinifera, 67.7%), chokeberry (Aronia melanocarpa, 14.5%), cherry (Prunus cerasium, 12%) and bilberry (Vaccinium myrtillus, 5.8%), while the other two drinks were specifically made by TINE SA for the present study. Optijuice was made of MANA Blue (85%) added polyphenol-rich extract from blackcurrant press-residue (15%), previously optimised for biological activity in vitro. Optijuice contained more total polyphenols than MANA Blue, but was lower in hydroxycinnamic acids, as this compound was lower in the blackcurrant press-residue than in MANA Blue. A placebo drink was developed with comparable amounts of energy, carbohydrates, K and colour to mimic the intervention juices. It contained Maltodextrin (6·2 g), sugar (6·2 g), KCl (280 mg), blueberry flavour (350±156, 25 mg), grape flavour (610±384, 20 mg), citric acid (0·01 mg, to pH 4) and dye (E122 and E25/azorubin/brilliant black, 5 mg), all per 100 g beverage. Subjects were provided with sufficient volume for daily intake of 500 ml for 12 weeks. The study beverages were supplied by TINE SA in identical white containers, each containing 1000 ml Optijuice, MANA Blue or placebo.

Beverage compounds

The total content of polyphenols was determined with the Folin–Ciocâlteu's method and determined as gallic acid equivalents in mg/100 g of sample as described previously. The pH differential absorbance method was used to determine the content of total monomeric anthocyanins, calculated as cyanidin-3-glucoside equivalents in mg/100 g of sample. Individual polyphenol compounds were analysed on an Agilent 1100 series HPLC system (Agilent Technologies) equipped with a diode array detector and a MSD XCT ion trap mass spectrometer as described previously. The polyphenols were quantified using cyanidin-3-glucoside, at 520 nm, for anthocyanins; rutin, at 360 nm, for flavonols; and chlorogenic acid, at 320 nm, for hydroxycinnamic acids. All the results are presented as mg/100 g of sample (online supplementary Table S1). The ferric-reducing antioxidant power was assayed as described by Benzie & Strain.

Study subjects

The volunteers were recruited by postal mail by 10 000 invitation letters to men and women, between 50 and 70 years living in Oslo, Norway, and listed in the National Population Registry, as well as by about 400 letters distributed to the lunch areas in public transport companies. The invitation letter did not ask for BP level, but for exclusion criteria including the use of regular BP-lowering medication, the presence of type 1 and 2 diabetes, smoking habit or a BMI above 35 kg/m². About 9% (n 921) subjects replied to the first invitation.
Of these, 737 were found eligible to be invited for a screening visit. At the screening visit (\( n = 627 \)), additional exclusion criteria, such as allergy to grapes, cherries, blueberries/bilberries, blackcurrant or chokeberries, changes of \( \pm 4 \) kg in body weight within the last 12 weeks before the start of the study, use of supplement for weight reduction, or of polyphenol-rich supplements and participation in other clinical trials or other planned activities (vacation, hospital admission, etc.), were recorded. At the same time, the volunteers’ BP was screened to be within the high normal range (130/85–139/89 mmHg) or stage 1–2 hypertension (140/90–179/109 mmHg), which was the main inclusion criteria. All subjects signed a written consent to participate. During the baseline visit (\( n = 207 \)), subjects who did not meet the BP criteria were further excluded from the study (\( n = 54 \)). Subjects initiating BP-lowering medication during the study, not following the drinking regimen (at least 80% compliance), not showing up on all visits, or incorrect BP measurements according to the procedure were also excluded from the analyses (Fig. 1).

**Study design**

The present study was a double-blind, placebo-controlled trial, and was conducted between December 2011 and June 2012. At baseline, subjects were randomly assigned to a study group consuming 500 ml/d of (1) placebo; (2) Optijuice; or (3) MANA Blue for 12 weeks. The subjects were instructed to record the consumed beverages in a provided diary. They were also asked to refrain from other juice products (except juices made of apples and oranges), and from antioxidant supplements (such as vitamin C) before the start of the study and during the course of the study. Apart from this, the subjects were encouraged to maintain their habitual diet, physical activity and lifestyle while enrolled in the study.

All the subjects made four visits (screening, baseline, 6-week visit and 12-week visit) during the study period. On the measurement days, the subjects had been fasting from midnight the day before. For the last visit, the subjects were asked to drink the last glass of study beverage between 20.00 and 22.00 hours the night before. All the visits were between 08.00 and 10.00 hours to avoid diurnal fluctuations.

**Blood pressure measurements**

Fasting SBP and DBP measurements were performed blinded by a trained personnel. Totally, three measurements at 1-min intervals were recorded after 10 min of rest in a waiting room followed by another 5 min in an investigation room where the subject sat in a resting chair with the cuff mounted

---

**Fig. 1.** Flow chart of study participants. BP, blood pressure.
Statistical analyses

We assumed a SD of the reduction of 11 mmHg, and based on an ANOVA test, we found that a total of 210 individuals would be needed to detect a difference in BP of 5 mmHg with a power of 80% and a significance level of 0.05. After screening process, 207 subjects were eligible for the study.

Changes in BP were analysed using the ‘mixed’ command for linear mixed models in IBM SPSS (software version 16.0.1; SPSS Inc.) treating time as categorical parameter, including a random intercept in the model and the following parameterisation: $\beta_0$, time + $\beta_1$ treatment + $\beta_2$ (time $\times$ treatment). BP estimates were based on the mixed model, and P values were generated from the SPSS test of fixed effects for the interaction term (time$\times$treatment) from the mixed model, as is the estimated difference in change between intervention and placebo groups at different time points.

Variability of BP was calculated as SD of the three measurements at each visit and further analysed by a mixed model as described above. The residuals of the SD showed a normal distribution. Baseline statistics summarised in Table 2 are presented as crude means with SD. Differences between groups at baseline were determined by ANOVA as were differences in the biochemical data. A comparison of first systolic blood pressure (SBP1) with mean systolic blood pressure (SBPmean) was done by paired t-test. A $P \leq 0.05$ was considered significant.

Subgroup analyses, as described above, were performed on hypertensive subjects (140–179 mmHg) and normotensive subjects (124–139 mmHg) based on SBP1 or SBPmean at baseline.

Results

Participant flow

Subjects who responded positively to the invitation letter corresponded to about 9% of the invited cohort ($n$ 905). Of these subjects, 737 were eligible after self-reporting and were invited for screening, and 627 persons attended the screening.
of BP and the interview. After the screening procedure, 420 subjects were excluded from the study because they did not fulfill the inclusion criteria or for other reasons. At baseline, another fifty-four subjects had BP below the eligibility criteria and were therefore, not included. During the study, nineteen subjects dropped out, leaving 134 subjects who completed the intervention (Fig. 1). At the end of the study, four data sets were excluded from the analyses according to the exclusion criteria. Hence, the study group for analyses consisted of 130 subjects, with forty-three in the placebo group, forty-one in the Optijuice group and forty-six in the MANA Blue group.

**Baseline characteristics of subjects**

At baseline, the mean SBP1 and first diastolic blood pressure (DBP1) for all the subjects were 143 and 81 mmHg, respectively, and the corresponding mean values of SBPmean and DBPmean were 141 and 82 mmHg, respectively. Neither the BP values nor the anthropometric measures were significantly different among the three study groups (Table 2).

**Effects on blood pressure in the polyphenol-rich juice groups**

At baseline, we observed that in the whole study group (n = 130), SBP1 was on average 2.5 mmHg higher (P < 0.001) than the SBPmean, and therefore, these two measures were analysed separately.

SBP1 was significantly reduced in both the Optijuice group and the MANA Blue intervention group at 6 weeks (P = 0.01 for both), but not after 12 weeks, compared with the placebo group (Table 3). There were no significant differences between the SBP1 time curves (P = 0.07) when analysing the (time x treatment) interaction over the full study period (12 weeks). Changes in DBP1 in the intervention groups were not different from those of the placebo group, neither for single time point nor for the complete time curve.

Since both intervention juices are very rich in polyphenols, we pooled the Optijuice and MANA Blue groups in the analysis to increase the statistical power. The SBP1 time curves for the pooled intervention group and placebo group were significantly different (P = 0.01). The (time x treatment) interaction revealed that after 6 weeks, SBP1 were reduced by 6.9 mmHg in the pooled group compared with the placebo (P < 0.001), while this effect was not seen after 12 weeks (Table 3). No effects were observed for DBP1.

We did not observe any significant differences between the groups when time curves for SBPmean or DBPmean were investigated (online supplementary Table S2), neither for all the three groups separated nor if the two juice groups were pooled.

**Larger effect of polyphenol-rich juice on blood pressure in hypertensive subjects compared with normotensive subjects**

Sub-analyses of the interventions on hypertensive subjects (SBP in the range of 140–179 mmHg) based on SBP1 at baseline showed that the SBP1 time curves were not significantly different among the three study groups (Table 2).

### Table 3. Blood pressure (BP) measurements: first BP measurement in all subjects* (Mean values and 95% confidence intervals)

<table>
<thead>
<tr>
<th>Group</th>
<th>SBP1 (mmHg)</th>
<th>MANA Blue</th>
<th>Optijuice</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>140.905</td>
<td>144.434</td>
<td>141.074</td>
<td>141.090</td>
</tr>
<tr>
<td>Optijuice</td>
<td>143.074</td>
<td>140.438</td>
<td>145.074</td>
<td>141.074</td>
</tr>
<tr>
<td>MANA Blue</td>
<td>143.494</td>
<td>141.173</td>
<td>144.891</td>
<td>140.891</td>
</tr>
<tr>
<td>Pooled</td>
<td>144.494</td>
<td>141.173</td>
<td>145.494</td>
<td>141.494</td>
</tr>
</tbody>
</table>

**Blood pressure (BP) measurements: first BP measurement in all subjects**

- **SBP1 (mmHg)**: 140.905, 143.074, 143.494, 144.494
- **DBP1 (mmHg)**: 80.4, 81.7, 81.9, 81.8

- **SBPmean (mmHg)**: 141.0, 144.8, 141.3, 141.4
- **DBPmean (mmHg)**: 81.0, 82.0, 81.9, 81.8

- **SBP1, first systolic blood pressure**
- **DBP1, first diastolic blood pressure**

**Diff. placebo, estimated differences in treatment groups from placebo group.**

- **Pooled group**
  - **SBP1**
    - 15.2, 12.4
  - **DBP1**
    - 6.7, 3.7

- **Optijuice group**
  - **SBP1**
    - 14.5, 11.7
  - **DBP1**
    - 7.2, 4.2

- **MANA Blue group**
  - **SBP1**
    - 14.1, 11.3
  - **DBP1**
    - 7.8, 4.8

- **P**
  - 0.001, 0.015
  - 0.001, 0.015

- **Interaction (time x treatment)**
  - 0.001, 0.015
  - 0.001, 0.015

- **P**
  - 0.07
  - 0.001

- **k**
  - 0.001
  - 0.001

- **P**
  - 0.001
  - 0.001

- **k**
  - 0.001
  - 0.001

- **P**
  - 0.001
  - 0.001

- **k**
  - 0.001
  - 0.001

- **P**
  - 0.001
  - 0.001

**P** value for the overall test of no (time x treatment) effect using the placebo and the pooled juice groups.

**P** value for the overall test of no (time x treatment) effect using the placebo and the two intervention groups.

**P** value for the overall test of no (time x treatment) effect using all the three treatment groups (the placebo and the two intervention groups).
different for the treatment groups (Table 4). In the pooled juice group, however, the SBP1 time curve was significantly different from the placebo group ($P=0.05$). This difference is explained by a significantly higher reduction in the pooled group after both 6 weeks ($P=0.03$) and 12 weeks ($P=0.04$) than the placebo group. DBP1 was not affected by the juice interventions (data not shown).

Changes of BP in normotensive subjects (range of 124–139 mmHg based on SBP1 at baseline) after the intervention are presented in Table 4. In the pooled analysis of Optijuice and MANA Blue groups, we observed significant differences for the SBP1 time curve compared with the placebo group ($P=0.02$). However, this significant difference seems to be due to a net increase in SBP1 in the placebo group after 6 weeks (5.5 mmHg) rather than a reduction in the juice groups. No effects were seen for DBP1 (data not shown).

No effects of the interventions in hypertensive or normotensive subjects, based on SBP mean at baseline, were observed in the SBP mean measures (online supplementary Table S3) or DBP mean measures (data not shown).

**Effects of polyphenol-rich juice on standard deviation as a measure of the variance of three blood pressure measurements**

BP variance is a relevant measure in CVD development\(^{22}\). We observed that the SD of the three measurements of SBP at each visit was reduced in the pooled juice group by 1.4 mmHg (6 weeks) and 1.7 mmHg (12 weeks). Compared with the placebo visit, this gave a significant reduction ($P=0.001$). In normotensive subjects, a significant difference between placebo and pooled groups was not observed (Table 5).

**Biomarker analyses**

Blood samples for haematological and biochemical analyses were collected at baseline and at the end of the study, at week 12. The mean baseline values were within the normal range for all markers (data not shown). The results showed that only ALAT was significantly different in the three groups during the time course ($P<0.001$), on average $-0.7$, $-8.9$ and $1.2$ units/l in the placebo, Optijuice and MANA Blue study groups, respectively. In the Optijuice group, two data sets were above normal range at baseline and reduced over 50% by the end of the study. These data sets were considered out of range and were removed before analyses not to create a false positive reduction in the Optijuice group. At baseline, the average values for ALAT were 25.2, 17.9 and 26.0 units/l for placebo, Optijuice and MANA Blue, respectively. At the end of the study, the average values for ALAT were 25.2, 17.9 and 26.0 units/l for placebo, Optijuice and MANA Blue, respectively.

**Anthropometric analyses**

Body composition and weight were determined at the first and last visits (baseline and week 12). There were no

---

**Table 4. Changes in first blood pressure in hypertensive and normotensive subjects**

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Mean</th>
<th>95 % CI</th>
<th>Mean</th>
<th>95 % CI</th>
<th>Mean</th>
<th>95 % CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP1 (mmHg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Placebo</strong></td>
<td>24</td>
<td>149.3</td>
<td>143.8, 154.8</td>
<td>145.8</td>
<td>134.4, 151.3</td>
<td>142.5</td>
<td>127.0, 148.0</td>
</tr>
<tr>
<td><strong>Optijuice</strong></td>
<td>23</td>
<td>154.0</td>
<td>148.5, 159.5</td>
<td>142.8</td>
<td>137.2, 148.3</td>
<td>140.7</td>
<td>135.2, 146.3</td>
</tr>
<tr>
<td><strong>MANA Blue</strong></td>
<td>25</td>
<td>152.8</td>
<td>147.6, 158.0</td>
<td>139.9</td>
<td>137.0, 147.4</td>
<td>142.2</td>
<td>135.7, 148.6</td>
</tr>
<tr>
<td>SBP1 (mmHg)</td>
<td>48</td>
<td>153.3</td>
<td>149.6, 157.1</td>
<td>142.5</td>
<td>138.7, 146.2</td>
<td>139.8</td>
<td>135.0, 144.5</td>
</tr>
<tr>
<td><strong>Pooled</strong></td>
<td>39</td>
<td>133.3</td>
<td>130.5, 136.0</td>
<td>132.5</td>
<td>129.8, 135.2</td>
<td>133.6</td>
<td>129.8, 137.4</td>
</tr>
<tr>
<td><strong>SBP1 (mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Placebo</strong></td>
<td>19</td>
<td>130.7</td>
<td>126.8, 134.7</td>
<td>126.2</td>
<td>122.7, 132.7</td>
<td>127.2</td>
<td>123.2, 131.7</td>
</tr>
<tr>
<td><strong>Optijuice</strong></td>
<td>21</td>
<td>132.9</td>
<td>130.5, 135.4</td>
<td>132.2</td>
<td>128.5, 135.9</td>
<td>134.6</td>
<td>130.4, 138.8</td>
</tr>
<tr>
<td><strong>MANA Blue</strong></td>
<td>21</td>
<td>133.9</td>
<td>130.6, 137.2</td>
<td>132.5</td>
<td>129.0, 136.0</td>
<td>134.0</td>
<td>130.4, 137.4</td>
</tr>
<tr>
<td><strong>Pooled</strong></td>
<td>39</td>
<td>133.3</td>
<td>130.5, 136.0</td>
<td>132.5</td>
<td>129.8, 135.2</td>
<td>133.6</td>
<td>130.4, 137.4</td>
</tr>
</tbody>
</table>

**Changes of BP in normotensive subjects (range of 124–139 mmHg based on SBP at baseline)**

- **Placebo**
- **Optijuice**
- **MANA Blue**

---

\(^{*}\) Data shown are estimated values generated from the mixed model. P values are also taken from the mixed model.

\(^{†}\) $P$ value for changes from baseline to weeks 6 and 12, respectively, compared with the placebo group.

\(^{‡}\) The placebo and the pooled juice groups.
significant differences in weight or body composition (data not shown).

**Discussion**

Previous epidemiological studies and some intervention studies have suggested a role for polyphenols in BP reduction\(^{(8,9,11,27)}\). The present study, which is the first placebo-controlled intervention study on the effects of berry juice on BP, strongly indicates that polyphenol-rich berry juice alone can reduce BP and short-time BP variation. We analysed changes of the first of three BP measurements (BP1), the mean of the two following measurements (BP\(_{\text{mean}}\)), as well as the BPV to evaluate the effect of the polyphenol-rich juices on BP.

The present results demonstrated that BP1 was significantly reduced in the pooled polyphenol-rich juice group compared with the placebo group. It is well known that the first recording in repeated BP measurements is usually higher than the next two recordings\(^{(28)}\), as observed in the present study. This may be regarded as a ‘white coat effect’\(^{(28)}\), i.e. an observed increased BP taken at a doctor’s office compared with BP measured at home or with ambulatory BP. In many studies, this measurement has, therefore, been excluded from the analyses. Probably, BP1 is more sensitive to stress and sympathetic activation, similar to the elevated BP observed during mental or acute stress tests\(^{(29–31)}\). The association between stress-related elevated BP and CVD is well established\(^{(32)}\). The present results suggest that a possible mechanism of the beneficial effects of fruits and berries on CVD could be through reduction of the elevated BP during stressful situations and not necessarily on the resting BP, which, in the present study, was not significantly changed during the intervention period.

Further, we observed that the BPV, determined by the SD of the three measurements at each visit, was reduced by the polyphenol-rich intervention. Akita \(\text{et al.}\)\(^{(33)}\) showed that cacao liquor polyphenols reduced BPV in rabbits. Hodgson \(\text{et al.}\) showed that black tea lowered the rate of BPV in human subjects\(^{(34)}\), although they were not able to detect the same effects by specific vitamin or grapeseed interventions\(^{(35)}\). The present study is the first to show a reduction in BPV in a clinical placebo-controlled intervention trial. The reduction in BPV may probably reduce the risk of CVD\(^{(22)}\) as both visit-to-visit and ambulatory BP are predictors of cardiovascular incidents\(^{(21,23)}\). Possible mechanisms behind these findings may be that high BPV leads to stress on the vessel wall, which may, again, result in damage and initiation of CVD. We defined BPV as the SD of the three SBP measurements over a time period of 3–4 min. Other studies have used SD of ambulatory or visit-to-visit BP measurements\(^{(22)}\), or even the slope of SBP from beat to beat\(^{(30)}\). We suggest that the variation in three SBP measurements over a time period of 3–4 min may also reflect a relevant pathophysiological condition similar to BPV determined by other methods.

We were surprised to observe that the reduction in SBP1 was most evident in the intervention group after 6 weeks (6·4 mmHg, pooled group) while only a 0·8 mmHg further
Polyphenol-rich juices reduce blood pressure

Both juices had high levels of total polyphenols and ferric-reducing antioxidant power, both measures of antioxidant capacity or reducing properties (Table 1). The amounts of total polyphenols and ferric-reducing antioxidant power in Optijuice, which contained the blackcurrant peel extract, were about 20% higher than in MANA Blue juice. The concentrations of flavonols were also somewhat higher (28%) in Optijuice, while the concentrations of total hydroxycinnamic acids were equal in the two juices, explained by the low content of hydroxycinnamic acids in blackcurrant. The main difference between the juices was the higher content of anthocyanins, the major polyphenol compounds in the juices, where Optijuice had about 5-fold higher concentration than MANA Blue. In addition, the composition of anthocyanins differed, Optijuice, naturally being especially rich in anthocyanins from blackcurrants (i.e. glucosides and rutinosides of delphinidin and cyanidin (online supplementary Table S1)). Despite these differences, we did not observe any differences on the effect on BP between these juices. In the present study, it was, therefore, not possible to reveal any effects of dose or content of polyphenols. We, therefore, chose to pool the two groups to increase the statistical power in several of the analyses.

In the present study, subjects were instructed to refrain from other juice products, from antioxidant supplements and otherwise encouraged to maintain their habitual diet, physical activity and lifestyle during the study. Our main intention with the present study was to investigate the effect of intake of 500 ml polyphenol-rich juice per d in an open randomised controlled trial with free-living subjects without any other constraints. Other polyphenol-rich beverages such as coffee, tea and wine have shown beneficiary effects on the risk factors of CVD, although not unambiguously on BP. A normal intake of these beverages or other polyphenol-rich foods may have affected BP in the present study, both by itself and by synergy with the study juices. However, since the present study was placebo controlled, we suggest that the effects in the study are caused by the study juices and not by lifestyle or intake of other polyphenol-rich foods.

Biochemical markers associated with polyphenol intake as well as BP changes were analysed. Of all the biochemical markers analysed, only ALAT, a liver damage marker, was significantly reduced in only the Optijuice groups, containing blackcurrant. The protective effect of polyphenols, in general (40), and blackcurrant, in particular (41), on the liver has previously been suggested. The average values of all biochemical markers tested in the study population were within normal range. In general, it is not desired to alter normal blood values by food intervention. We were, therefore, not surprised that the study juices did not lead to other changes in the biochemical markers tested in the present study.

Conclusions

In the present study, the polyphenol-rich juice significantly reduced SBP1 in a group of middle-aged individuals. The reduction was more pronounced in hypertensive than in normotensive subjects. Further, we found that the juice also reduced BPV.

Our results suggest that a possible mechanism of the beneficial effects of fruits and berries for CVD protection could be through reduction of the stress-sensitive BP and not necessarily reduction of the resting BP. If future studies can confirm...
these findings, we suggest that such juice may be beneficial for subjects with high BP and may contribute to postpone introduction of hypertensive drugs.

Supplementary material

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0007114515000562

Acknowledgements

The authors thank the volunteers who participated in the present study. The authors acknowledge Findus, Lier, Norway, for producing the blackcurrant press-residue extract and TINE SA for providing the study beverages. Mona Ringstad, Nofima, is acknowledged for performing the analysis of ascorbic acid, total polyphenols and monomeric anthocyanins. Kari Holte, Anne Randi Engst (Department of Nutrition), Hege Hardersen and Anette Brantzæg (external support) provided highly appreciated and valuable contribution to the study.

The present study was supported by TINE SA and The Research Council of Norway (project 186902/110). The investigators conducted the study, were responsible for data retrieval and management, and performed the data analyses and wrote the article. The contractual agreement between the University of Oslo and TINE SA allowed the sponsor to review and comment on the article; however, the investigators remained solely responsible for its content and the decision to submit the results for publication. Hence, TINE SA had no role in the design and analyses of the study or in the writing of this article.

R. B. has an interest in AS Vitas, Oslo, Norway. The other authors declare no competing financial interests.

The authors’ contributions are as follows: T. E. T. was involved in the study design, recruitment of subjects, test sampling from subjects, analyses and interpretation of the data, statistical analyses, and drafting and finalising the manuscript; L. H. was involved in the study design, recruitment of subjects, test sampling from subjects, analyses and interpretation of the data, statistical analyses, and revision of the manuscript; S. K. B. was involved in the study design, statistical analyses, interpretation of the data and revision of the manuscript; K. A. was involved in the study design, interpretation of the data and revision of the manuscript; S. A. W. was involved in the recruitment of subjects, test sampling from subject, analyses of blood samples and revision of the manuscript; I. P. was involved in the study design, test sampling from subjects, interpretation of the data and revision of the manuscript; A. S. K. was involved in the study design and in the revision of the manuscript; K. R. was involved in the study design, medical advice, interpretation of the data and revision of the manuscript; P. O. I. was involved in the study design, medical advise, interpretation of the data and revision of the manuscript; R. B. was involved in the study design, interpretation of the data and revision of the manuscript.

References


